drugset / Trial / NCT02638038

This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years

NCT02638038

Phase 2 Completed 228 enrolled InteKrin Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, parallel group study comparing two doses of INT131( 3 mg and 1 mg) administered orally (PO) daily (QD) versus placebo 1 tablet PO QD in subjects with treatment-naïve RRMS for ≤ 3 years.

Timeline

Start
2015-02
Primary completion
2016-12-12
Completion
2016-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject INT131 Other / unclassified 1 mg Oral
Subject INT131 Other / unclassified 3 mg Oral